Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more

Conditions: Chickenpox
Interventions: Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 41
States / cities: Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Diabetes Mellitus, Type 2
Interventions: high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 112
States / cities: Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more

Conditions: Seizures, Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more

Conditions: Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more

Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Interventions: ION440, Sham procedure; Drug · Procedure
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: San Diego, California • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Migraine Headaches
Interventions: ELS-M11, Placebo; Drug
Lead sponsor: Achelios Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Charleston, South Carolina

Conditions: Ischemia-Reperfusion Injury, Kidney Diseases
Interventions: Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: GLYX-13, IV normal saline; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Actinic Keratosis (AK)
Interventions: RLS-1496 1.0% cream; Drug
Lead sponsor: Rubedo Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Hot Springs, Arkansas • New Brighton, Minnesota • Omaha, Nebraska + 1 more

Conditions: Coronary Artery Disease
Interventions: RespirAct; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Asthma
Interventions: Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Placebo Inhaltion Powder; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more

Conditions: Fibromyalgia
Interventions: ASP8062, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Oceanside, California • Torrance, California + 21 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: PF-06835919, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Generalized Anxiety Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 40
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more

Conditions: Hidradenitis Suppurativa
Interventions: ATI-450, Placebo oral tablet; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 17 more

Conditions: Fibromyalgia
Interventions: Prolonged Nightly Fasting, Health Education Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Tuberculosis
Interventions: MK-7762 (TBD09), Placebo; Drug · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 80
States / cities: Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more

Conditions: Migraine
Interventions: Ubrogepant, Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Orlando, Florida • Atlanta, Georgia • Austin, Texas + 1 more

Conditions: Insulin Resistance
Interventions: (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose, Placebo; Drug · Other
Lead sponsor: EncuraGen, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: AV-1, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

Evaluate RLS-1496 Topical Cream for Actinic Keratosis

Utilizing Carbon Dioxide for Assessing Coronary Blood Flow in Subjects With Coronary Artery Disease

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Prolonged Nightly Fasting in Fibromyalgia

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers